{"id":100481,"date":"2025-12-08T18:25:13","date_gmt":"2025-12-08T18:25:13","guid":{"rendered":"https:\/\/www.europesays.com\/se\/100481\/"},"modified":"2025-12-08T18:25:13","modified_gmt":"2025-12-08T18:25:13","slug":"usa-bolag-rusar-efter-resultat-for-viktminskningspiller","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/100481\/","title":{"rendered":"USA-BOLAG RUSAR EFTER RESULTAT F\u00d6R VIKTMINSKNINGSPILLER"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Amerikanska bolaget Structure Therapeutics meddelar &#8221;positiva&#8221; \u00f6vergripande resultat fr\u00e5n det kliniska Access-programmet f\u00f6r aleniglipron f\u00f6r behandling av personer som lever med fetma och\/eller \u00f6vervikt med minst en viktrelaterad samsjuklighet, skriver bolaget i ett pressmeddelande.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Aleniglipron \u00e4r en oral, en g\u00e5ng dagligen, icke-peptid sm\u00e5molekyl\u00e4r agonist av glukagonliknande peptid-1 (GLP-1)-receptorn.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Resultaten inkluderar 36-veckorsdata fr\u00e5n fas 2b-studien Access. I denna n\u00e5dde aleniglipron kliniskt meningsfull och statistiskt signifikant placebojusterad medianviktnedg\u00e5ng om 11,3 procent f\u00f6r 120 milligramdosen efter 36 veckor. I den prospektiva Access 2-studien n\u00e5dde aleniglipron 240 milligram en placebojusterad medianviktnedg\u00e5ng om upp till 15,3 procent efter 36 veckor.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Aleniglipron visade god s\u00e4kerhetsprofil, i linje med andra GLP-1-preparat.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">&#8221;Sammantaget st\u00f6djer dessa positiva resultat fortsatt utveckling av aleniglipron in i klinisk fas 3&#8221;, heter det.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Structured var upp \u00f6ver 30 procent i den amerikanska f\u00f6rhandeln.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Kristine Trapp +46 8 5191 7927<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Nyhetsbyr\u00e5n Direkt<\/p>\n","protected":false},"excerpt":{"rendered":"STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Amerikanska bolaget Structure Therapeutics meddelar &#8221;positiva&#8221; \u00f6vergripande resultat fr\u00e5n det kliniska Access-programmet f\u00f6r aleniglipron f\u00f6r&hellip;\n","protected":false},"author":2,"featured_media":77249,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,34,31,33,32,30],"class_list":{"0":"post-100481","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-se","12":"tag-svenska","13":"tag-sverige","14":"tag-sweden","15":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115685354568505905","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/100481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=100481"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/100481\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/77249"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=100481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=100481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=100481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}